• Developed and Tested by Partner CCrest Laboratories
• Aimed for Distribution with NUBU Pharmaceuticals inAustralasia

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is thrilled to announce updates regarding its manufacturing plans to create homogenised natural psilocybin microdosing capsules.

CCrest Laboratories Inc. ("CCrest Laboratories"), a Montreal-based cGMP pharmaceutical laboratory that holds a Controlled Drugs & Substances Dealer's License from Health Canada, has completed dehydration and homogenization and has produced a Certificate of Analysis of Red Light Holland's natural psilocybin truffles grown in the Netherlands that were imported to Canada under a Health Canada licence.

Further, the Company has selected and sourced child proof packaging for its microdosing capsules. The packaging includes a HDPE plastic bottle with Child Resistant Closures (CRC) and an auto lock external box (see Image 1 and 2). As disclosed previously, and subject to obtaining Health Canada's approval for export, the natural psilocybin microdosing capsules are intended to be distributed in Australasia by NUBU Pharmaceuticals ("NUBU Pharmaceuticals"), a leading medical cannabis company based in New Zealand with distribution ties to Australia.

"We are very hopeful that our prestigious partnerships with CCrest and NUBU Pharmaceuticals will bring about an excellent natural psilocybin microdosing product that has the potential of helping many people," said Todd Shapiro, Red Light Holland CEO and Director. "We will continue to carefully yet aggressively seek legal opportunities to increase responsible access to natural psilocybin around the world."

"We are very excited to now have a first potential destination for the natural psilocybin microdosing capsules we are developing, and to make significant progress towards the end product," said Alex Grenier, CEO of Shaman Pharma and President of CCrest Laboratories.

"This is a great first step towards getting the Microdosing capsules distributed in Australasia," said Mark Dye, Co-Founder and CEO of NUBU.

Australia has recently, on February 3, 2023, announced a down-listing of psilocybin in its list of controlled substances to allow psychiatrists to prescribe psilocybin to patients suffering from treatment resistant depression. The change in scheduling was announced to take effect on July 1, 2023.

Image 1 - 40cc Pill Bottle and CRC Cap

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2017/163274_48e190dec408782c_001full.jpg

Image 2 - Autolock Box

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/2017/163274_48e190dec408782c_002full.jpg

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-643-TRIP (8747)
Email: todd@redlight.co
Website: www.RedLight.co

About Shaman Pharma Corp.

Shaman Pharma is a federally registered Canadian corporation with the mission to power outstanding psychedelic life science innovation. Accelerating time-to-market through its portfolio of assets, Shaman Pharma launches and consolidates revenue-driven pharma-biotech life sciences ventures focused on supplying psychedelic drugs & novel active ingredients.

About NUBU Pharmaceuticals

Formed in 2017, NUBU Pharmaceuticals (New Zealand's largest medicinal cannabis distribution company) specializes in the distribution of therapeutics from the new frontier of medicine, including cannabis and psychedelics. The company also develops New Zealand-made cannabis products for export markets, harnessing two of New Zealand's great strengths, it's innovative culture and unique botanicals.

For additional information on NUBU Pharmaceuticals:

Mark Dye
Co-Founder/Chief Executive Officer
Tel: +649-360 0204
Email: mark.dye@nubupharma.com
Website: www.nubupharma.com